Detalhe da pesquisa
1.
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Blood
; 137(24): 3327-3338, 2021 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33786588
2.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Blood
; 136(1): 93-105, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32202637
3.
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Blood
; 135(15): 1204-1213, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31876911
4.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet
; 395(10232): 1278-1291, 2020 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305093
5.
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Haematologica
; 106(9): 2364-2373, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730844
6.
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Cancer
; 126(20): 4485-4497, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32757302
7.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet
; 391(10121): 659-667, 2018 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241979
8.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(4): 323-32, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26641137
9.
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
J Pharmacol Exp Ther
; 363(2): 240-252, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882879
10.
The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.
Haematologica
; 107(6): 1460-1465, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172559
11.
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
Ann Hematol
; 94(2): 249-56, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25178517
12.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Lancet Oncol
; 15(1): 48-58, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24332241
13.
Neutrophil elastase as a versatile cleavage enzyme for activation of αvß3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment.
Front Pharmacol
; 15: 1358393, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38495100
14.
Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription.
Cancer Res Commun
; 3(11): 2268-2279, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882668
15.
Discovery of VIP236, an αvß3-Targeted Small-Molecule-Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors.
Cancers (Basel)
; 15(17)2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37686656
16.
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Leukemia
; 37(2): 326-338, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376377
17.
A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types.
Cancers (Basel)
; 14(2)2022 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35053556
18.
Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
J Clin Pharmacol
; 62(6): 812-822, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34897701
19.
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
Clin Cancer Res
; 28(7): 1285-1293, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35046056
20.
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
J Med Chem
; 64(15): 11651-11674, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264057